iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
iBio (NASDAQ:IBIO) has announced promising preclinical results for its novel amylin receptor agonist antibody in obesity treatment. The engineered antibody demonstrated a significant 60% reduction in acute food intake in mouse models, comparable to the 67% reduction achieved by a clinically advanced DACRA peptide.
This marks the third target from iBio's partnership with AstralBio, leveraging their AI-enabled antibody discovery platform to develop selective amylin receptor targeting treatments. The approach shows potential for both monotherapy and combination therapy with GLP-1 receptor agonists, with current amylin analogs achieving up to 22.7% weight loss in combination with semaglutide and 11.8% as monotherapy in clinical development.
iBio (NASDAQ:IBIO) ha annunciato risultati preclinici promettenti per il suo nuovo anticorpo agonista del recettore dell'amylina nel trattamento dell'obesità. L'anticorpo ingegnerizzato ha mostrato una significativa riduzione del 60% nell'assunzione acuta di cibo in modelli murini, comparabile alla riduzione del 67% ottenuta da un peptide DACRA clinicamente avanzato.
Questo rappresenta il terzo target della collaborazione tra iBio e AstralBio, che sfrutta la loro piattaforma di scoperta di anticorpi abilitata dall'IA per sviluppare trattamenti selettivi mirati al recettore dell'amylina. L'approccio mostra potenzialità sia come monoterapia sia in combinazione con agonisti del recettore GLP-1, considerando che gli analoghi dell'amylina attuali raggiungono fino a un 22,7% di perdita di peso in combinazione con semaglutide e l’11,8% come monoterapia in fase di sviluppo clinico.
iBio (NASDAQ:IBIO) ha anunciado resultados preclínicos prometedores para su nuevo anticuerpo agonista del receptor de amilina en el tratamiento de la obesidad. El anticuerpo diseñado mostró una reducción significativa del 60% en la ingesta aguda de alimentos en modelos murinos, comparable a la reducción del 67% lograda por un péptido DACRA clínicamente avanzado.
Este es el tercer objetivo de la asociación entre iBio y AstralBio, que aprovecha su plataforma de descubrimiento de anticuerpos habilitada por IA para desarrollar tratamientos selectivos dirigidos al receptor de amilina. El enfoque muestra potencial tanto para monoterapia como para terapia combinada con agonistas del receptor GLP-1, considerando que los análogos actuales de amilina alcanzan hasta un 22,7% de pérdida de peso en combinación con semaglutida y un 11,8% como monoterapia en desarrollo clínico.
iBio (NASDAQ:IBIO)는 비만 치료를 위한 새로운 아밀린 수용체 작용 항체에 대한 유망한 전임상 결과를 발표했습니다. 이 설계된 항체는 쥐 모델에서 급성 음식 섭취를 60% 감소시키는 유의한 효과를 보였으며, 이는 임상적으로 진전된 DACRA 펩타이드가 달성한 67% 감소와 유사한 수준입니다.
이는 iBio와 AstralBio의 협력으로 AI 기반 항체 발견 플랫폼을 활용해 선택적 아밀린 수용체 표적 치료제를 개발하는 세 번째 타깃입니다. 이 접근법은 단독 요법과 GLP-1 수용체 작용제와의 병용 요법 모두에 가능성을 보여주며, 현재 아밀린 유사체는 세마글루타이드와 병용 시 최대 22.7% 체중 감소, 단독 요법 시 임상 개발 단계에서 11.8%의 체중 감소를 달성하고 있습니다.
iBio (NASDAQ:IBIO) a annoncé des résultats précliniques prometteurs pour son nouvel anticorps agoniste du récepteur de l’amylin dans le traitement de l’obésité. L’anticorps conçu a démontré une réduction significative de 60 % de la consommation alimentaire aiguë chez des modèles murins, comparable à la réduction de 67 % obtenue par un peptide DACRA cliniquement avancé.
Ceci représente la troisième cible issue du partenariat entre iBio et AstralBio, qui utilise leur plateforme de découverte d’anticorps assistée par IA pour développer des traitements ciblant sélectivement le récepteur de l’amylin. L’approche montre un potentiel à la fois en monothérapie et en thérapie combinée avec des agonistes du récepteur GLP-1, les analogues actuels de l’amylin atteignant jusqu’à 22,7 % de perte de poids en combinaison avec le sémaglutide et 11,8 % en monothérapie en développement clinique.
iBio (NASDAQ:IBIO) hat vielversprechende präklinische Ergebnisse für seinen neuartigen Amylin-Rezeptor-Agonisten-Antikörper zur Behandlung von Fettleibigkeit bekannt gegeben. Der entwickelte Antikörper zeigte in Mausmodellen eine signifikante 60%ige Reduktion der akuten Nahrungsaufnahme, vergleichbar mit der 67%igen Reduktion, die durch ein klinisch fortgeschrittenes DACRA-Peptid erreicht wurde.
Dies ist das dritte Ziel der Partnerschaft von iBio mit AstralBio, wobei deren KI-gestützte Antikörper-Entdeckungsplattform genutzt wird, um selektive Therapien mit Ziel auf den Amylin-Rezeptor zu entwickeln. Der Ansatz zeigt Potenzial sowohl als Monotherapie als auch in Kombination mit GLP-1-Rezeptor-Agonisten, wobei aktuelle Amylin-Analoga in Kombination mit Semaglutid bis zu 22,7% Gewichtsverlust und als Monotherapie in der klinischen Entwicklung 11,8% Gewichtsverlust erreichen.
- Significant 60% reduction in food intake in mouse models, comparable to leading DACRA peptide (67%)
- AI-enabled platform allows precise targeting of amylin receptor subtypes for potentially improved efficacy
- Potential for both monotherapy and combination therapy with GLP-1 receptor agonists
- Third successful target from iBio-AstralBio partnership showing platform validation
- Results are only preclinical stage, requiring extensive further testing
- Will face competition from established obesity treatments and other amylin analogs in development
- Efficacy in humans yet to be demonstrated
Insights
iBio's amylin receptor antibody shows promising obesity treatment potential with 60% food intake reduction in mice, comparable to leading peptide treatments.
The preclinical data presented by iBio represents a significant technical advancement in obesity therapeutics. Their engineered amylin receptor agonist antibody demonstrated a
What makes this approach scientifically notable is the selective activation of the amylin receptor rather than dual agonism. The company's AI-enabled platform appears capable of precisely targeting amylin receptor subtypes, potentially offering improved tolerability while maintaining efficacy. This selectivity could provide a meaningful differentiation from current approaches.
The mechanism targets amylin (islet amyloid polypeptide), a pancreatic hormone that regulates satiety and gastric emptying. By enhancing meal-ending metabolic signals through receptor agonism, the therapy prolongs feelings of fullness. The heterodimeric G protein-coupled receptor (GPCR) targeted here represents a compelling alternative to GLP-1 approaches dominating the current obesity treatment landscape.
Importantly, the press release references clinical data showing amylin analogs achieving weight reduction of up to
While promising, these remain early-stage results from a mouse model, with significant development hurdles ahead before potential clinical application. The scientific approach appears sound, but standard pharmaceutical development risks apply.
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist
Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases
Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of next-generation antibody therapies, today announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake in a mouse model of obesity by
The successful iBio-AstralBio collaboration now includes multiple novel engineered antibody agonists with a wide range of profiles targeting the amylin receptor, a heterodimeric G protein-coupled receptor (GPCR).
“Emerging clinical data suggest selective activation of the amylin receptor—rather than dual agonism of the amylin and calcitonin receptors—can match or even exceed DACRA efficacy, with improved tolerability,” said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “Our AI-enabled antibody discovery platform allows us to precisely dial in that selectivity and specifically target the amylin receptor and even its subtypes. This new program underscores iBio’s commitment to developing next-generation therapies to address the limitations of current treatments in the fast-growing obesity market.”
Amylin, or islet amyloid polypeptide (IAPP), is a pancreatic B-cell hormone shown to regulate satiety and delay gastric emptying. When activated through receptor agonism, it enhances meal-ending metabolic signals that prolong the feeling of fullness. Amylin receptors (AMYRs), composed of heterodimeric GPCRs, represent a compelling therapeutic target for obesity and other cardiometabolic diseases. iBio’s approach leverages its proprietary Drug Discovery Platform and advanced AI platform to discover innovative antibodies with exceptional selectivity and potency. This allowed the discovery of molecules capable of agonizing a single AMYR subtype or having balanced agonism at multiple receptors (i.e., DACRA-like agonism profile). This precise and versatile GPCR agonist discovery is thought to allow the identification of a best-in-class therapeutic candidate for an optimal profile of quality weight loss, gastrointestinal tolerability, and lean mass preservation.
Other amylin analogs currently under clinical development have achieved reduced body weight in obese patients of up to
References
1. https://www.hcplive.com/view/cagrisema-achieves-22-7-weight-loss-in-phase-3-redefine-1-trial
2. https://www.biopharmadive.com/news/novo-nordisk-cagrisema-study-results-diabetes-weight-loss/742008/
Conference Call Details
iBio will host a conference call today, June 24, at 8:30 a.m. ET to discuss new pre-clinical data and the Company’s obesity pipeline.
The webcast of the live call may be accessed on the Investors section of the iBio website at ir.ibioinc.com/news-events/ir-calendar. A replay of the webcast will be available on the iBio website for approximately 60 days following the presentation.
To join the live call, participants need to access this link for dial-in numbers and a unique participation code.
About iBio, Inc.
iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases, accelerating the development of novel antibodies for obesity and cardiometabolic diseases in partnership with AstralBio Inc., the positive early results supporting iBio’s approach to antibody-based amylin receptor agonism for the treatment of obesity, iBio’s engineered antibody potentially offering differentiated advantages in dosing and tolerability, developing next-generation therapies to address the limitations of current treatments in the fast-growing obesity market, leveraging iBio’s proprietary Drug Discovery Platform and advanced AI platform to discover innovative antibodies with exceptional selectivity and potency and iBio’s approach targeting the amylin receptor holding promise not only for enhancing the weight-loss efficacy seen with GLP-1 receptor agonists but also as a monotherapy option for patients who are intolerant or insufficiently responsive to GLP-1-based interventions. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of amylin receptor to be a successful target for obesity and cardiometabolic diseases; iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2024 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
FAQ
What were the key results of iBio's (IBIO) obesity treatment study?
How does iBio's obesity treatment approach differ from current treatments?
What is the potential weight loss effectiveness of amylin-based treatments?
How many targets has iBio's partnership with AstralBio produced?
When is iBio's conference call to discuss the obesity treatment results?
